Elevated Expression of Girdin in the Nucleus Indicates Worse Prognosis for Patients with Estrogen Receptor-Positive Breast Cancer

Annals of Surgical Oncology

Volumn 21, Issue 4, 2014, Pages 648-656

  Peng, Wen Ting ^a,b   Hu, Xin ^a   Yao, Ling ^a   Jiang, Yi Zhou ^a,b   Shao, Zhi Ming ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN BINDING PROTEIN; CCDC88A PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN KINASE B; VESICULAR TRANSPORT PROTEIN;

ADULT; AGED; BREAST TUMOR; CELL NUCLEUS; CHEMISTRY; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PHOSPHORYLATION; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL NUCLEUS; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MICROFILAMENT PROTEINS; MIDDLE AGED; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; VESICULAR TRANSPORT PROTEINS;

EID: 84939877043     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3746-y     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA. 1999;96(16):9212–17.
3. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.
4. Enomoto A, Murakami H, Asai N, et al. Akt/PKB regulates actin organization and cell motility via Girdin/APE. Dev Cell. 2005;9(3):389–402.
5. Anai M, Shojima N, Katagiri H, et al. A novel protein kinase B (PKB)/AKT-binding protein enhances PKB kinase activity and regulates DNA synthesis. J Biol Chem. 2005;280(18):18525–35.
6. Ghosh P, Garcia-Marcos M, Bornheimer SJ, Farquhar MG. Activation of Galphai3 triggers cell migration via regulation of GIV. J Cell Biol. 2008;182(2):381–93.
7. Jun BY, Kim SW, Jung CK, et al. Expression of girdin in human colorectal cancer and its association with tumor progression. Dis Colon Rectum. 2013;56(1):51–7.
8. Garcia-Marcos M, Jung BH, Ear J, Cabrera B, Carethers JM, Ghosh P. Expression of GIV/Girdin, a metastasis-related protein, predicts patient survival in colon cancer. FASEB J. 2011;25(2):590–9.
9. Liu C, Xue H, Lu Y, Chi B. Stem cell gene Girdin: a potential early liver metastasis predictor of colorectal cancer. Mol Biol Rep. 2012;39(9):8717–22.
10. Liu C, Zhang Y, Xu H, et al. Girdin protein: a new potential distant metastasis predictor of breast cancer. Med Oncol. 2012;29(3):1554–60.
11. Ling Y, Jiang P, Cui SP, et al. Clinical implications for girdin protein expression in breast cancer. Cancer Invest. 2011;29(6):405–10.
12. Wang L, Xiao X, Li D, et al. Abnormal expression of GADD45B in human colorectal carcinoma. J Transl Med. 2012;10:215.
13. Lin B, Utleg AG, Gravdal K, et al. WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clin Cancer Res. 2008;14(5):1397–1406.
14. Halvorsen OJ, Rostad K, Oyan AM, et al. Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer. Clin Cancer Res. 2007;13(3):892–7.
15. Metzger-Filho O, Sun Z, Viale G, et al. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol. 2013;31(25):3083–90.
16. Chen S, Jiang Y, Huang L, et al. The residual tumor autophagy marker LC3B serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. Clin Cancer Res. 2013;19(24):6853–62.
17. Ghosh P, Garcia-Marcos M, Farquhar MG. GIV/Girdin is a rheostat that fine-tunes growth factor signals during tumor progression. Cell Adh Migr. 2011;5(3):237–48.
18. Weng L, Enomoto A, Ishida-Takagishi M, Asai N, Takahashi M. Girding for migratory cues: roles of the Akt substrate Girdin in cancer progression and angiogenesis. Cancer Sci. 2010;101(4):836–42.
19. Miyake H, Maeda K, Asai N, et al. The actin-binding protein Girdin and its Akt-mediated phosphorylation regulate neointima formation after vascular injury. Circ Res. 2011;108(10):1170–9.
20. Jiang P, Enomoto A, Jijiwa M, et al. An actin-binding protein Girdin regulates the motility of breast cancer cells. Cancer Res. 2008;68(5):1310–18.
21. Garcia-Marcos M, Ghosh P, Farquhar MG. GIV is a nonreceptor GEF for G alpha i with a unique motif that regulates Akt signaling. Proc Natl Acad Sci USA. 2009;106(9):3178–83.
22. Martelli AM, Tabellini G, Bressanin D, et al. The emerging multiple roles of nuclear Akt. Biochim Biophys Acta. 2012;1823(12):2168–78.
23. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9.
24. Dhillon S. Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer. Drugs. 2013;73(5):475–85.
25. Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res. 2007;13(7):1950–4.